Last August we were informed of the selection of our AVECEN project to participate in the Living Lab of the European project IN4AHA, promoted by 10 partners from 7 European countries, with Galician Health Cluster as the Spanish representative.
Innovation Network for Active and Healthy Ageing (IN-4-AHA) is a EU-funded Coordination and Support Action (CSA) that contributes to the cross-border scale-up of tested and ready-to-use applications in health and social care. The project will bring together both the support and the demand sides as well as the end-users, engage with local and regional ecosystems, stakeholder groups and organisations. The main outcome of this cooperation is an innovation scale-up model that is validated by stakeholders and complemented by a clear implementation roadmap, an innovation impact evaluation toolkit and a strategy for long-term investments.
During these months we have had the opportunity to learn from international experts in technology and the healthcare sector about best practices to accelerate AVECEN’s arrival on the market. As a complement to these activities and with the support of IN4AHA, we will be attending SLUSH, the world’s leading startup event, which this year will be held in Helsinki, on 1 and 2 December. In just two days, we will have a chance to hear from the key players of the startup world, get the most hands-on entrepreneurial advice, see the up-and-coming startups of today, and connect with the most relevant people to our project.
With our participation in the IN4AHA and LabSaúde Living Labs, the entities that are part of the consortium, we take another step forward in our firm will to bring technological innovation closer to users, being part of an open innovation ecosystem focused on people and in a real environment. With this, we give continuity to a project initiated in 2018, co-funded by the Conecta Peme Programme of the Galician Innovation Agency (GAIN) and which aims to improve the lives of people with dementia, their caregivers and their families, helping to prevent and self-manage neurodegenerative diseases characterised by a progressive deterioration of cognitive functions such as Parkinson’s or Alzheimer’s disease..